Investing.com - CorMedix (NASDAQ: CRMD) reported second quarter EPS of $-0.250, in line with the analyst estimate of $-0.250. Revenue for the quarter came in at $810K versus the consensus estimate of $1.66M.
CorMedix's stock price closed at $3.78. It is down -26.170% in the last 3 months and down -11.270% in the last 12 months.
CorMedix saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See CorMedix's stock price’s past reactions to earnings here.
According to InvestingPro, CorMedix's Financial Health score is "fair performance".
Check out CorMedix's recent earnings performance, and CorMedix's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar